Press Releases

Commemorating World Lung Day's 2023 theme, “Access to prevention and treatment for all: Leave No One Behind,” Alkem is launching an ambitious nationwide initiative aimed at raising awareness about the importance of lung health and the need for early diagnosis and correct treatment. Alkem is committed to reaching every corner of India through this initiative, responding to the increasing number of people suffering from respiratory diseases. To drive their mission, ALKEM is orga

Coya Therapeutics, Inc. a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Tregs, today announced licensing of the exclusive, worldwide rights of a proprietary Exosome Engineering Technology from CMU with potential applications across multiple indications, including neurodegeneration, autoimmune, and oncology. This technology is versatile, permitting the modification of exosomes from different biological sources while o

TME Pharma N.V. a biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announced today that two abstracts on the ongoing NOX-A12 GLORIA Phase 1/2 trial in first-line brain cancer (glioblastoma) were selected for presentation at upcoming international scientific conferences. The oral presentation at the European Society for Medical Oncology (ESMO) Congress taking place in Madrid, Spain, on October 20-24, 20

MC2 Therapeutics announced today that it has acquired option rights from Regranion, LLC to exclusively license Regranion’s RGRN-305 for the treatment of all human diseases, incl, oral treatment of HS globally, excluding the greater China region. RGRN-305 is an orally administered new chemical entity in preparation for clinical phase 2b. Under the agreement, Regranion will receive an upfront option payment with additional development and sales milestones as well as royalties, o

Experts from Austria have now published new recommendations on the current best treatment options for advanced or metastatic biliary tract cancer. The new consensus favors personalized second-line therapies that target specific genetic alterations of tumor cells. For first-line therapies, the addition of modern immunotherapeutics (checkpoint inhibitors) to standard chemotherapy is recommended under certain circumstances. These recommendations are made in light of new therapeutic options and s

Inhibrx, Inc. (Nasdaq: INBX), a clinical-stage biopharmaceutical company focusing on therapeutics for oncology and rare diseases, has announced that Chiesi Farmaceutici S.p.A ("Chiesi") has chosen not to exercise its option for ex-North American rights to develop and commercialize INBRX-101, intended for treating patients with emphysema due to Alpha-1 Antitrypsin Deficiency ("AATD"). The option for Chiesi to obtain an exclusive license to develop and commercializ

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported important progress related to the regulatory pathway for tabelecleucel (tab-cel®) in the U.S. Following productive discussions between Atara and the U.S. Food and Drug Administration (FDA), the FDA and Atara are now aligned on anal

Biofourmis, a leading global technology-enabled care delivery company, announced today the release of its expanded Digital Clinical Trials solution within the Biofourmis platform for biopharma and other life sciences companies. The solution offers robust digital tools and resources for trial sponsors and investigators aimed at accelerating drug development and improving access and diversity while also reducing costs. Biofourmis' Digital Clinical Trials solution includes a techno

Caliway Biopharmaceuticals (Caliway), a biopharmaceutical company focusing on breakthrough medical aesthetics and inflammatory medicine discovery of small-molecule therapeutics, announced the completion of subject recruitment in the CBL-0201EFP Phase 2-stage 2 study. The CBL-0201EFP Phase 2-stage 2 study is an open-label trial that will evaluate the efficacy, safety, and tolerability of CBL-514 in treating subjects with moderate to severe cellulite. The study actually enrolled a tot

the leading global nutraceuticals contract development and manufacturing organization (CDMO) – will further expand its offering in the consumer health market, building on last month’s ‘pharma targeted’ softgel launch, with the introduction of a range of herbal gummies for trending consumer health categories. The three new formulations are designed to help its partners, particularly pharma and OTC brands who want to grow in the active health space, accelerate